$3.71
0.02[0.54%]
At close: Apr 26
$3.71
0[0.00%]
After Hours: 4:20PM EDT
MaxCyte
(NASDAQ:MXCT)MaxCyte Stock (NASDAQ:MXCT), Analyst Ratings, Price Targets, Predictions
MaxCyte Inc has a consensus price target of $7.33, established from looking at the 12 latest analyst ratings. The last 3 analyst ratings were released from Stephens & Co., Stephens & Co., and BTIG on April 23, 2024, March 13, 2024, and March 13, 2024. With an average price target of $10 between Stephens & Co., Stephens & Co., and BTIG, there's an implied 169.54% upside for MaxCyte Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Stephens & Co.
BTIG
Craig-Hallum
William Blair
Cowen & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for MaxCyte
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/23/2024 | MXCT | Buy Now | MaxCyte | $3.71 | 196.5% | Stephens & Co. | Jacob Johnson | → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 03/13/2024 | MXCT | Buy Now | MaxCyte | $3.71 | 196.5% | Stephens & Co. | Jacob Johnson | → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 03/13/2024 | MXCT | Buy Now | MaxCyte | $3.71 | 115.63% | BTIG | Mark Massaro | $10 → $8 | Maintains | Buy | Get Alert |
| 11/29/2023 | MXCT | Buy Now | MaxCyte | $3.71 | 88.68% | Craig-Hallum | Matt Hewitt | → $7 | Initiates | → Buy | Get Alert |
| 10/05/2023 | MXCT | Buy Now | MaxCyte | $3.71 | 223.45% | Stephens & Co. | Jacob Johnson | → $12 | Reiterates | Overweight → Overweight | Get Alert |
| 03/28/2023 | MXCT | Buy Now | MaxCyte | $3.71 | 223.45% | Stephens & Co. | Jacob Johnson | → $12 | Reiterates | → Overweight | Get Alert |
| 08/15/2022 | MXCT | Buy Now | MaxCyte | $3.71 | 196.5% | BTIG | Mark Massaro | $10 → $11 | Maintains | Buy | Get Alert |
| 08/24/2021 | MXCT | Buy Now | MaxCyte | $3.71 | 412.13% | Stephens & Co. | Jacob Johnson | — | Initiates | → Overweight | Get Alert |
| 08/24/2021 | MXCT | Buy Now | MaxCyte | $3.71 | — | William Blair | Matt Larew | — | Initiates | → Outperform | Get Alert |
| 08/24/2021 | MXCT | Buy Now | MaxCyte | $3.71 | — | Cowen & Co. | Max Masucci | — | Initiates | → Outperform | Get Alert |
| 08/24/2021 | MXCT | Buy Now | MaxCyte | $3.71 | 385.18% | Stifel | Daniel Arias | — | Initiates | → Buy | Get Alert |
| 08/24/2021 | MXCT | Buy Now | MaxCyte | $3.71 | 492.99% | BTIG | Mark Massaro | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for MaxCyte (MXCT)?
The latest price target for MaxCyte (NASDAQ: MXCT) was reported by Stephens & Co. on April 23, 2024. The analyst firm set a price target for $11.00 expecting MXCT to rise to within 12 months (a possible 196.50% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MaxCyte (MXCT)?
The latest analyst rating for MaxCyte (NASDAQ: MXCT) was provided by Stephens & Co., and MaxCyte reiterated their overweight rating.
When was the last upgrade for MaxCyte (MXCT)?
There is no last upgrade for MaxCyte.
When was the last downgrade for MaxCyte (MXCT)?
There is no last downgrade for MaxCyte.
When is the next analyst rating going to be posted or updated for MaxCyte (MXCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MaxCyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MaxCyte was filed on April 23, 2024 so you should expect the next rating to be made available sometime around April 23, 2025.
Is the Analyst Rating MaxCyte (MXCT) correct?
While ratings are subjective and will change, the latest MaxCyte (MXCT) rating was a reiterated with a price target of $0.00 to $11.00. The current price MaxCyte (MXCT) is trading at is $3.71, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.